Skip to content
From the lab to the market: Dr. Jarrod Sandow’s journey from academia to industry.
“One of the greatest lessons I’ve learned is that innovation doesn’t happen in isolation.”

Dr. Jarrod Sandow, Chief Product Officer at IonOpticks, recently returned to where it all began—at the Walter and Eliza Hall Institute of Medical Research (WEHI). This homecoming wasn’t just a nostalgic visit, but a full-circle moment for the visionary scientist-turned-entrepreneur, who delivered an inspiring presentation at WEHI’s Entrepreneurship Seminar.

As an alumnus of WEHI, Dr. Sandow leads the commercialisation of IonOpticks’ technology, which was developed at the very institute that laid the foundation for his groundbreaking work. With this dual perspective—one foot firmly planted in his academic past and the other in the fast-moving world of industry—Jarrod offered attendees a rare glimpse into the evolution of his career, the challenges of commercialisation, and the lessons learned along the way.

The WEHI Entrepreneurship Seminar series, designed to inspire researchers to think beyond the lab and consider the broader impact of their work, was the perfect platform for Jarrod’s story. It was clear from the start that the audience was eager to hear more than just theory—they wanted real-world insight into how to turn ideas into tangible, commercially viable products.

Researchers at WEHI probe Dr Sandow about the practicalities of moving from the lab to the market.

In his talk, he recounted his career trajectory, which began deeply rooted in academic research at the University of Adelaide in South Australia. Moving to Melbourne and eventually landing in WEHI’s proteomics facility, Jarrod’s initial focus was purely to improve the results being produced by the facility, however, as the potential for manufacturing reproducible and reliable chromatography became clearer, he found himself at a crossroads—stay at WEHI in a traditional research role or take the plunge into the uncertain waters of industry.

This decision, as Jarrod explained, was far from easy. The allure of academia, with its structure and clear path, often stands in stark contrast to the unpredictability and risk associated with entrepreneurship. But, as Jarrod shared, his passion for seeing his research make a tangible impact on the world led him to choose the latter.

For many researchers, the idea of transitioning from academia to industry can be intimidating. The skills honed in a research lab—meticulous attention to detail, problem-solving, and patience—don’t always seem immediately transferable to the fast-paced, high-stakes world of business. However, as Jarrod highlighted, these very skills are essential when it comes to innovation and entrepreneurship.

“I found myself straddling both worlds for a while,” Jarrod admitted, reflecting on his journey. “Leaving WEHI was a tough decision. There’s a comfort in the familiar, and academic research was my passion for so long. But in the end, the potential of what we were building at IonOpticks—and the impact it could have—was too powerful to ignore.”

Jarrod’s honesty about the internal struggle resonated with many, some of whom are likely facing similar dilemmas. How do you balance the passion for scientific discovery with the realities of bringing that discovery to market? Jarrod’s answer: you can’t do it alone.

After his presentation, Jarrod opened the floor to questions, and a lively Q&A session ensued. Young researchers, eager to follow in his footsteps, asked pointed questions about the practicalities of moving from the lab to the market. They wanted to know how ideas incubated in a research setting could be scaled, commercialised, and ultimately turned into sustainable businesses.

Jarrod’s advice was clear: “Don’t be afraid to fail, and don’t be afraid to ask for help.” He stressed the importance of finding the right partners, mentors, and collaborators to help bridge the gap between academia and industry. “No one person has all the answers,” he said. “But together, you can figure it out. And WEHI is a great place to start these ideas. They’ve got a strong model for incubation and commercialisation—that’s exactly where we started.”

He also touched on the financial realities of starting a business, a topic often overlooked in academic circles. “Funding is always a challenge, especially in the early days,” Jarrod noted. “But if you believe in your product and are willing to put in the hard work, there are people out there who will believe in it too.”

As the Q&A continued, Jarrod’s genuine passion for both science and entrepreneurship became even more apparent. He encouraged the audience to not only think about their research in terms of academic publications but also in terms of its potential to solve real-world problems.

As the session drew to a close, Jarrod took a moment to reflect on IonOpticks’ journey over the last seven years. “When we first started, we had no idea where this would go,” he said. “We believed in the technology, but there were so many unknowns. It’s only by working together with our dedicated team, staying focused, and pushing through the challenges that we’ve been able to get to where we are today.”

For Jarrod, the opportunity to return to WEHI and share his story was not only a moment of reflection but also a chance to inspire the next generation of researchers to think big, take risks, and, most importantly, believe in their ideas.

As attendees filed out to a brief networking session, many were left with much to think about. For some, it was a reaffirmation of their passion for research. For others, it was the spark they needed to start considering the commercial potential of their own work. But for all, Jarrod’s journey stood as a testament to the power of innovation, perseverance, and collaboration in making a lasting impact.

Dr. Jarrod Sandow’s journey from early researcher to Chief Product Officer of IonOpticks serves as an inspiring reminder that the transition from lab bench to boardroom is possible—and that, with the right mindset, collaboration, and determination, innovation can indeed change the world.

Previous
Next
Latest News

13 March 2025

Widening the lens: how Karl Krull is taking single-cell proteomics from methods to meaning

Estimated Reading Time: 6 minutes

Karl Krull, a PhD candidate working in Jeroen Krijgsveld‘s group at the DKFZ German Cancer Research Center in Heidelberg, is building innovative workflows that push single-cell proteomics towards dramatically higher … Continued

25 February 2025

From Parasites to Proteomics: how Dr. Samantha Emery-Corbin is Bridging Biology and Big Data

Estimated Reading Time: 6 minutes

Dr Samantha Emery-Corbin, a research fellow at the Monash Proteomics and Metabolomics Platform, is in the midst of a clinical trial that could lead to a transformation of how sepsis … Continued

24 February 2025

IonOpticks announces strategic global expansion with key leadership appointments

Estimated Reading Time: 3 minutes

PRESS RELEASE Melbourne, February 24 2025: IonOpticks, a world-leading provider of chromatography solutions, today announce two key appointments to strengthen its global operations, enhancing access and support for the LC-MS … Continued

11 February 2025

From technical innovation to clinical impact: how Patricia Skowronek is making proteomics methods accessible to more researchers

Estimated Reading Time: 5 minutes

Patricia Skowronek, a postdoctoral researcher working with Prof. Matthias Mann at the Max Planck Institute of Biochemistry, is actively working to make proteomics methods faster, more precise, and more accessible … Continued

21 January 2025

Building a world-class team for a world-class vision: Dr Jarrod Sandow.

Estimated Reading Time: 3 minutes

In the world of science and discovery, change is constant, driven by continuous advancements and new insights. As the pace of medical advancements and scientific breakthroughs accelerates, the tools researchers … Continued

15 January 2025

Size matters: how Dr. Mike Lanz is exploring overlooked features of cells

Estimated Reading Time: 5 minutes

Dr. Mike Lanz, who completed his Ph.D. at Cornell University before joining Stanford and the Chan Zuckerberg Biohub, has uncovered something unexpected: cell size is a fundamental determinant of protein … Continued

Share: